REGEN-LAB
15.5.2023 14:01:26 CEST | Business Wire | Press release
Regen Lab, a global commercial-stage medical technology company specializing in the research, development, registration, manufacturing and commercialization of proprietary tissue engineering products announces that its best-in-class medical devices REGENKIT®, CELLULAR MATRIX fig® and Arthrovisc® have obtained the CE certification under the EU Regulation 2017/745 on Medical Devices (MDR).
REGENKIT® is a preparation of Platelet-Rich Plasma (PRP), CELLULAR MATRIX fig®, a combination of PRP and Hyaluronic Acid (HA), and Arthrovisc®, HA filled syringes.
Based on the examination of its Quality Management System and Technical Documentation, these new CE certificates delivered to Regen Lab SA (EU authorized representative Regen Lab France SAS) by the notified body BSI are all valid for five years with a starting validity date on April 25, 2023, and an expiry date on April 24, 2028.
Imposed on all manufacturers and distributors operating in the European Union, the EU MDR 2017/745, applicable since May 26, 2021, in the European Union, is meant to mandatorily replace by 2028 the existing European Medical Device Directives (MDD 93/42/EEC). These EU regulations on medical devices aim at establishing a modern and more robust regulatory framework to protect public health and patient safety. This certification has considerably increased the amount of technical and clinical validation data required on medical devices across the EU, to address the need for a better traceability and transparency in safety.
In relation to the EU MDR certification of its products, Regen Lab successfully renewed its ISO13485:2016 and MDSAP certifications with a Quality Assurance System meeting the requirements of the European MDR EU 2017/745 Regulation in December 2022.
The certifications obtained reinforces Regenlab’s competitive position in the PRP market alone and in combination with HA.
Regen Lab autologous tissue engineering solutions are based on an extemporaneous preparation of PRP from the patient’s own blood and combined therapy (PRP combined with HA).
Regen Lab is a vertically integrated group with extensive R&D, regulatory and manufacturing expertise. To date, Regen Lab’s patented technologies* are available in over 90 countries worldwide and have been used to treat patients in various therapeutic areas (musculoskeletal, dermo-esthetics, wound care and urogenital) leading to the publication of over 200 clinical studies projects. The Company’s products are manufactured in the Group factories in Le Mont sur Lausanne (Switzerland), Brooklyn (New York, USA) since 2022, and in Les Ulis (Paris region, France) starting from Q3 of 2023.
More info about Medical Devices Regulation: https://ec.europa.eu/growth/single-market/european-standards/harmonised-standards/medical-devices_en
About Regen Lab
Based in Mont-sur-Lausanne, Switzerland, Regen Lab is a global commercial-stage medical technology company specialized in the research, development, registration, manufacturing and commercialization of proprietary tissue engineering solutions. The Company's solutions are commercialized in more than 90 countries and generated total revenues of €40 million in 2022. The core technology of the Company focuses on the design of solutions for autologous platelet-rich plasma (PRP) based procedures, consisting in reinjecting the patient's own platelets into tissue lesions in order to stimulate tissue healing. The Company's original medical devices, commercialized primarily under the RegenKit brand, have been CE marked EU-MDR 2017/745 and approved by FDA and CFDA and are routinely used by physicians worldwide for the treatment of a wide variety of main indications currently including joint osteoarthritis, tendinopathies and dermo-esthetics. The Company's products are manufactured in the Group factories in Le Mont-sur-Lausanne (Switzerland), New York (USA) since Q3 2022 and Les Ulis (Paris region, France) starting Q3 2023, which the Company has built to meet its anticipated increasing demand for its new products.
More info about RegenLab: https://www.regenlab.com
*For a list of Regenlab’s patents see: https://www.regenlab.com/patents
Regenkit®, Cellular Matrix fig®, Arthrovisc, Regenlab®, Regenplasma®, Regencell®, RegenACR®, THT® are registered or pending trademarks of Regen Lab SA or RegenLab USA LLC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005412/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2026 Esri User Conference to Focus on Creating a More Intelligent World with GIS25.6.2026 14:00:00 CEST | Press release
More Than 18,000 Attendees Expected for World's Largest GIS Conference in San Diego The 2026 Esri User Conference will be held from July 13 to 17 in San Diego, California. This year's theme is "GIS—Creating a more intelligent world." Jack Dangermond, president and founder of Esri, and Kristine Tompkins, president and cofounder of Tompkins Conservation, will be the keynote speakers in the Plenary Session. Esri, the global leader in geographic information system (GIS) technology, today announced speakers and the conference theme for the 2026 Esri User Conference. The conference will be held from July 13 to 17 at the San Diego Convention Center in San Diego, California. This year's theme of "GIS—Creating a more intelligent world" will emphasize how GIS turns the science of "where" into shared understanding and coordinated action—at the scale of communities, enterprises, and the planet. Kristine Tompkins, president and cofounder of Tompkins Conservation, will join Esri president Jack Dange
Copeland Releases FY2025 Global Impact Report Highlighting Energy Efficiency, Safety and Innovation Progress25.6.2026 14:00:00 CEST | Press release
Scope 1 and Scope 2 greenhouse gas emissions declined nearly 20%1Near-term reduction targets validated by the Science Based Targets InitiativeGlobal Total Recordable Incident Rate improved to 0.21, outperforming the industry average by over 90% Copeland, a global leader in compression technologies and controls solutions, has released its second annual Global Impact Report. The report highlights the company’s Fiscal Year 2025 (FY25) progress across environmental sustainability, workplace safety and community impact, guided by its Purpose, Performance and People pillars. Copeland has advanced its sustainability commitments through three strategic areas of focus: Performance-Driven Decarbonization: Copeland reduced Scope 1 and Scope 2 greenhouse gas emissions by 20% year-over-year, advancing toward its Science Based Targets initiative (SBTi)-validated goal of a 55% absolute reduction by FY33, using FY23 as a baseline.2 Renewable energy procurement and onsite solar generation accounted for
ExaGrid Wins 4 Industry Awards at the Storage Awards25.6.2026 14:00:00 CEST | Press release
ExaGrid has won 11 awards for its Tiered Backup Storage so far in 2026 ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that the company was honored with four industry awards during the 23rd annual Storage Awards ceremony, “The Storries,” held in London on June 18, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625584191/en/ The ExaGrid team headed to the stage four times throughout the Storage Awards ceremony in London to accept awards for ExaGrid Tiered Backup Storage. Photo courtesy of Storage Awards. ExaGrid was named Data Protection Company of the Year, Immutable Storage Company of the Year, Storage Company of the Year, andjointly received the Storage Solution of the Year - Corporate award with key channel partner Convergent Technology. ExaGrid continues
SUTEL Deploys Tecnotree Platform to Modernize Mobile Prepaid Registration and Strengthen Digital Security and Trust in Costa Rica25.6.2026 13:26:00 CEST | Press release
New Tecnotree platform will provide a faster, safer, and more accessible registration process for prepaid mobile users The Superintendence of Telecommunications (SUTEL) is advancing the modernization of Costa Rica’s Mobile Prepaid Registration System through the implementation of a new technological platform provided by Tecnotree designed to strengthen user identification processes, enhance regulatory compliance, and improve the overall customer experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625307287/en/ This initiative is part of SUTEL’s ongoing efforts to promote digital transformation within the telecommunications sector while reinforcing security, transparency, and trust in digital communications across the country. The new Tecnotree platform incorporates advanced identity verification mechanisms, biometric authentication capabilities, and fraud prevention tools that will enable a more efficient and secur
MRM Health Strengthens Board with Michel Detheux as Chairman and Hans-Jürgen Wörle as Independent Director as MH002 Advances Through Phase 2b25.6.2026 13:00:00 CEST | Press release
The appointments position MRM Health for its next key clinical, partnering and financing milestones MRM Health, a clinical-stage biotech developing microbiome-based therapies for immune-mediated diseases, today announced the appointment of two experienced industry leaders to its Board of Directors as the Company enters a pivotal phase of growth. With its lead program, MH002, in Phase 2b clinical development, recent FDA Fast Track designation and a €55 million Series B financing, MRM Health is strengthening its Board to support the Company through its next clinical, strategic and financing milestones. Michel Detheux, PhD, has been appointed Chairman of the Board of Directors, taking over from Werner Cautreels. Prof. Dr. med. Hans-Jürgen Wörle joins the Board as an Independent Director. “MRM Health is entering a pivotal phase, with MH002 advancing into Phase 2b clinical development and significant momentum across the business. The appointments of Michel and Hans-Jürgen significantly stre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom